RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the fourth quarter and full year ended December 31, 2011 and other business updates.
Total product revenue was $155.2 million for the fourth quarter of 2011, a 31% increase compared to $118.5 million for the fourth quarter of 2010. Total product revenue for the full year of 2011 was $540.5 million, a 60% increase compared to $337.0 million for the full year of 2010. XIFAXAN® revenue for the fourth quarter of 2011 was $107.2 million, a 29% increase compared to $83.0 million for the fourth quarter of 2010. XIFAXAN revenue for the full year of 2011 was $371.7 million, a 48% increase compared to $250.5 million for the full year of 2010.
